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Abstract
Clostridium difficile infections have become a major healthcare concern in the last decade during which the emergence of
new strains has underscored this bacterium’s capacity to cause persistent epidemics. c-di-GMP is a bacterial second
messenger regulating diverse bacterial phenotypes, notably motility and biofilm formation, in proteobacteria such as Vibrio
cholerae, Pseudomonas aeruginosa, and Salmonella. c-di-GMP is synthesized by diguanylate cyclases (DGCs) that contain a
conserved GGDEF domain. It is degraded by phosphodiesterases (PDEs) that contain either an EAL or an HD-GYP conserved
domain. Very little is known about the role of c-di-GMP in the regulation of phenotypes of Gram-positive or fastidious
bacteria. Herein, we exposed the main components of c-di-GMP signalling in 20 genomes of C. difficile, revealed their
prevalence, and predicted their enzymatic activity. Ectopic expression of 31 of these conserved genes was carried out in V.
cholerae to evaluate their effect on motility and biofilm formation, two well-characterized phenotype alterations associated
with intracellular c-di-GMP variation in this bacterium. Most of the predicted DGCs and PDEs were found to be active in the
V. cholerae model. Expression of truncated versions of CD0522, a protein with two GGDEF domains and one EAL domain,
suggests that it can act alternatively as a DGC or a PDE. The activity of one purified DGC (CD1420) and one purified PDE
(CD0757) was confirmed by in vitro enzymatic assays. GTP was shown to be important for the PDE activity of CD0757. Our
results indicate that, in contrast to most Gram-positive bacteria including its closest relatives, C. difficile encodes a large
assortment of functional DGCs and PDEs, revealing that c-di-GMP signalling is an important and well-conserved signal
transduction system in this human pathogen.
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Introduction
Clostridium difficile is a Gram-positive, anaerobic, spore-forming
bacterium causing mild diarrhea to fulminant colitis in humans.
Due to spreading of hypervirulent and high toxin-producing
strains, C. difficile has caused in the last decade several epidemics in
Europe and North America where it is now the leading cause of
nosocomial diarrhea [1–3]. Its ability to sporulate allows this
bacterium to remain dormant for years and survive to harsh
conditions such as gastric acid after ingestion or the presence of
oxygen in the environment. C. difficile-associated diseases are
commonly associated with antibiotic usage, which creates a
favorable niche for C. difficile to grow and cause infection in part
by disrupting the gut microflora.
Bis-(39-59)-cyclic dimeric guanosine monophosphate (c-di-GMP)
is a bacterial second messenger controlling diverse bacterial
phenotypes mostly known to be involved in the transition from
free-living, motile to biofilm lifestyle in Gram-negative bacteria
[4,5]. c-di-GMP has also been shown to be involved in the
development and cell cycle control in Caulobacter crescentus [6,7],
and the modulation of virulence in several pathogens such as Vibrio
cholerae, Vibrio vulnificus, Bordetella pertussis or Pseudomonas aeruginosa
[8–11]. c-di-GMP is synthesized from 2 GTP molecules by
enzymes named diguanylate cyclases (DGCs) that contain a
GGDEF domain [12]. It is degraded respectively into pGpG or 2
GMP by phosphodiesterases (PDEs) that contain an EAL (PDEA)
or a HD-GYP domain [13,14]. GGDEF domains were named by
Hecht and Newton according to their conserved amino acid motif
GG[D/E]EF [12]. EAL and HD-GYP domains are also named
based on conserved amino motifs within these domains [13,14].
Whole genome analysis of a large number of bacterial species has
revealed that the number of genes coding for enzymes involved in
c-di-GMP turn-over varies widely between different species [15].
Genomes of proteobacteria generally encode a much wider array
of such enzymes compared to those of Gram-positive bacteria. For
instance, 66 genes coding for predicted enzymes involved in c-di-
GMP turn-over are found in Shewanella oneidensis,6 2i nV. cholerae,
41 in Pseudomonas aeruginosa,2 9i nEscherichia coli,6i nBacillus subtilis
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GMP’s input in the regulation of phenotypes within Gram-positive
bacteria. GdpS, the sole predicted staphylococcal GGDEF
domain-containing protein, positively regulates biofilm formation
in both S. aureus and S. epidermidis, and expression of protein A, a
major virulence factor in S. aureus. However, GdpS does not
appear to be an active DGC in vitro and its C-terminal GGDEF
domain is not involved in these two phenotypes [16,17].
Although the enzymes producing and degrading c-di-GMP
share customary domains in all bacteria, when known, the
downstream effectors and pathways regulating the different
phenotypical responses are usually different. c-di-GMP-sensing
proteins containing the characterized c-di-GMP-binding PilZ
domain [18] and some non-PilZ proteins are known c-di-GMP
binding receptors. In E. coli and related bacteria, the PilZ domain-
containing protein YcgR was found to decrease motility by
interacting with the flagellar motor to control its direction and
rotation speed upon binding of c-di-GMP [19,20]. In V. cholerae,
VpsT, a key transcription regulator that inversely regulates the
expression of genes associated with motility and biofilm formation,
was only recently found to be active following binding of c-di-
GMP to its atypical receiver domain [21]. Recently, the first c-di-
GMP-binding riboswitches (c-di-GMP-I) have been discovered in
the genomes of V. cholerae, C. difficile and other bacteria [22].
Riboswitch Cd1 of C. difficile is located upstream of the large
operon coding for the synthesis of the flagellum and was found to
have an ‘‘off’’ switch action on transcription in an in vitro
transcription assay and in b-galactosidase assays in B. subtilis [22].
Additionally, self-splicing of an unusual group I intron in C. difficile
genome was found to be allosterically controlled by a c-di-GMP-II
riboswitch aptamer, likely enabling the translation of a putative
surface protein upon c-di-GMP binding [23]. Furthermore, 37
genes of C. difficile 630 that encode putative proteins containing
GGDEF and/or EAL domains are available in the SignalCensus
database [24]. Together, these observations suggest that c-di-GMP
is a key signalling component in this emerging pathogen; yet
studies on proteins regulating the intracellular c-di-GMP level, i.e.
DGCs and PDEs, are still lacking.
The identification and characterization of enzymes producing
or degrading c-di-GMP is a critical step to determine and
understand the relevance of this second messenger in C. difficile’s
lifecycle and virulence. In this study, we analyzed the prevalence
and conservation of genes coding for putative DGCs and PDEAs
in the genomes of 20 C. difficile isolates. Thirty-one conserved
genes were assayed for their ability to encode functional DGC or
PDEAs by evaluating the effect of their expression in V. cholerae.
Most of these proteins conferred phenotypes that were consistent
with their predicted function in our heterologous expression
model. Our results indicate that, unlike the vast majority of Gram-
positive bacteria including the Clostridiaceae, C. difficile regulates
its intracellular c-di-GMP pools via a plethora of functional DGCs
and PDEAs.
Results
Domain composition and activity prediction of putative
DGCs and PDEAs encoded by C. difficile 630
Initial examination of the Pfam database 24.0 [25] for proteins
involved in c-di-GMP turn-over in C. difficile 630, correlated to
data provided by the NCBI’s SignalCensus database [24], reveals
a total of 37 proteins containing a GGDEF (Pfam PF00990) and/
or an EAL (Pfam PF00563) domain: 18 proteins have a GGDEF
domain, one protein contains an EAL domain and 18 proteins
have both GGDEF and EAL domains. Proteins containing both
GGDEF and EAL domains have been shown to act either as
DGCs or as PDEAs, or to exhibit both activities [14,26,27].
Furthermore, not all proteins containing a GGDEF or an EAL
domain have been shown to exhibit DGC or PDEA activity.
Several conserved amino acids in the GGDEF and EAL domains
are predicted to be important to confer enzymatic activity [28,29],
among which the highly conserved motifs GG[D/E]EF and
EXLR, respectively. These motifs and other conserved amino acid
residues were sought for in the primary sequences of the 37
putative c-di-GMP-signalling proteins encoded by the genome of
C. difficile 630 by multiple sequence alignment (Figure 1). Briefly,
among those 37 proteins, 15 are most likely active DGCs, 18 could
be active PDEAs, 1 protein (CD0522) could either be an active
DGC and/or PDEA, and 3 contain a predicted catalytically
inactive GGDEF domain (Table S1). Except for CD0522, all the
proteins with both GGDEF and EAL domains were predicted to
be PDEAs having an inactive GGDEF partner domain since these
have a degenerated GG[D/E]EF motif. Most of the 37 proteins
are predicted to have at least one sensor domain, transmembrane
regions or a signal peptide region.
Distribution of the putative c-di-GMP–signalling
components in C. difficile
To assess whether c-di-GMP signalling components are
conserved within the species C. difficile, orthologs of the proteins
identified in strain 630 were exhaustively sought for in 19 other
partially or completely sequenced C. difficile genomes using tblastn.
Most genes found in C. difficile 630 are conserved in all the strains
examined with 31 of the 37 GGDEF and/or EAL proteins having
an ortholog in at least 15 strains and only CD2753 and CD2754
being unique to strain 630 (Figure 2A). The putative glycosyl-
transferase CD2545, the sole protein predicted to contain a PilZ
domain (Pfam PF07238), has orthologs in all the other analyzed
strains (Figure 2A). Furthermore, two RNA targets (named herein
Cd1-a and 84Cd, respectively) that have been shown to bind c-di-
GMP, the riboswitch Cd1 located upstream of the flagellum
synthesis operon, and the self-splicing group I intron (tandem
riboswitch-ribozyme) are conserved in a subset of strains [22,23].
Author Summary
c-di-GMP is a bacterial intracellular signalling molecule
regulating motility, biofilm formation, cell cycle control, or
virulence in Gram-negative bacteria. The function and
importance of this molecule still remain unknown in Gram-
positive bacteria, even in important emerging pathogens
such as Clostridium difficile, which causes from mild to
deadly intestinal infections and has lately been on the rise
in the healthcare setting and in the community. Here, we
expose in the genomes of C. difficile strains a large number
of conserved genes encoding proteins involved in the
synthesis, degradation, or sensing of c-di-GMP, in contrast
with most other Gram-positive bacteria including C.
difficile’s closest relatives. We confirmed the activity of
most of these well-conserved proteins in a microorganism
for which typical behavior alterations associated with
variation of the intracellular c-di-GMP pools are known. We
further confirmed the c-di-GMP synthesis and degradation
activities of two purified C. difficile proteins. Our results
indicate that c-di-GMP signalling is important in the
lifecycle of this pathogen. This finding is particularly
exciting because the c-di-GMP signalling network could
serve as a target for the development of new drugs against
C. difficile-associated diseases that are commonly associ-
ated with antibiotic usage.
c-di-GMP Turn-Over in Clostridium difficile
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downstream effectors clearly follows the phylogenetic distribution
of the strains (Figure 2A and 2B). Interestingly, the cluster of 10
hypervirulent NAP1/BI/027 strains (cluster CD196/2007855 in
Figure 2B) regroups the strains encoding the lowest number of c-
di-GMP signalling components.
Like CD2753 and CD2754 that are specific to C. difficile 630, we
assumed that other strains could also encode c-di-GMP signalling
proteins that were absent from all of the other strains. The
Microbial Signal Transduction database (MiST2) [30], which
currently provides data for 14 out of our 19 strains, contains 3
putative c-di-GMP turn-over proteins that are absent from C.
difficile 630’s proteome. Notably, CdifA_020200002673, is unique
to strain ATCC43255 (Figure 2A), and is the only HD-GYP
domain-containing protein detected in C. difficile. Based on analysis
of amino acid conservation, it is predicted to have both DGC and
PDE enzymatic activities (Figure S1). To identify additional strain-
specific genes encoding c-di-GMP signalling proteins, we per-
formed profile hidden-Markov model (profile HMM) searches
with the Pfam HMMs for GGDEF, EAL, HD and PilZ conserved
domains using HMMER3 software against the proteomes of
strains 2007855, BI1, BI9, CF5, M120 and M68 as predicted by
GeneMark.hmm (Table S2). No additional c-di-GMP-signalling
proteins were detected. Besides CD2545, no other PilZ domain-
containing protein was found. Finally, no GGDEF, EAL, HD-
GYP or PilZ domain-containing proteins were found to be
encoded by C. difficile plasmids pCD630, pCD6, pCDBI1 or the
300 kb putative phage or plasmid from BI1 (Table S2).
The remarkable prevalence of c-di-GMP-signalling components
among C. difficile strains suggests that c-di-GMP is an important
second messenger in this bacterium. The functionality of the 31
most conserved GGDEF and/or EAL domain proteins among C.
difficile strains (Figure 2A) was therefore assessed to confirm their
biological activity.
Heterologous expression of DGC and PDEA encoding
genes in V. cholerae
To the best of our knowledge, no model of Gram-positive
bacteria is currently available to efficiently and reliably evaluate in
vivo the enzymatic activity of proteins regulating the intracellular
levels of c-di-GMP. Moreover, to circumvent the tedious
laboratory procedures associated with working with C. difficile
and the lack of information regarding the phenotypes regulated by
c-di-GMP in this bacterium, assessment of the enzymatic activity
of the 31 putative DGCs and PDEAs (cloned from C. difficile 630)
was carried out by heterologous expression in V. cholerae.
Characteristic phenotype alterations associated with variations of
the intracellular c-di-GMP concentration of V. cholerae are easily
observable and measurable. High levels of intracellular c-di-GMP
concentrations increase biofilm formation and decrease motility
whereas lower c-di-GMP concentrations cause the opposite effects
[31]. As expected, ectopic expression of most of the predicted
DGCs containing the canonical GG[D/E]EF motif decreased cell
motility (Figure 3A) and increased biofilm formation (Figure 3C),
supporting the hypothesis that these C. difficile proteins are genuine
and functional DGCs (Table S1). Replacement of the second
glycine of the GGDEF motif by site-directed mutagenesis has been
shown to greatly reduce the enzymatic activity of other DGCs
[32,33]. Such a mutation in CD1420 (mutant G204E) abolished
alterations of both biofilm and motility phenotypes (Figure 4A, 4B
and 4C) confirming that the phenotypical alterations observed in
V. cholerae are linked to the enzymatic activity of this functional C.
difficile DGC. Moreoever, the expression of CD1420 in V. cholerae
N16961 led to a dramatic increase of the c-di-GMP level
compared to the same strain expressing LacZ (Figure S2B and
S2D, Text S1). Furthermore, we observed that CD1015, CD1185
and CD1420, the DGCs causing the strongest phenotypical shifts
(Figure 3A and 3C), lacked the amino acid motif RXXD that is
part of the retro-inhibition site (I-site) of the GGDEF domain
(Figure 1) [34]. The putative DGC CD2887 significantly enhanced
biofilm formation without affecting the motility of V. cholerae.
Interestingly, CD2887 contains a GGEEY motif instead of the
canonical GG[D/E]EF motif suggesting that it might not be a
functional DGC. However, Malone and colleagues [35] showed
that upon substitution of the F amino acid residue for a Y residue
in the A-site, the DGC WspR of Pseudomonas fluorescens retains its
activity. Unlike the putative DGCs presented above, several
predicted DGCs that appear to possess all the conserved amino
acid residues necessary for c-di-GMP synthesis (e.g. CD2385 and
CD3365) did not modulate biofilm formation or motility of V.
cholerae in our experimental conditions. Yet we cannot conclude
that these putative DGCs are not functional since they might not
have been produced, may have been unstable or may lack the
appropriate activating signal in the heterologous host. Unexpect-
edly, CD0537, which also has a canonical A-site, did not enhance
biofilm formation but enhanced cell motility by ,60%. While this
increase is notable compared to other DGCs, it remained very
modest compared to the increase promoted by PDEAs (see below)
suggesting that in our experimental setting, this putative DGC was
not functional. The unexpected result on motility could result from
partial sequestration of intracellular c-di-GMP by CD0537’s I-site
upon overexpression of the protein. Additionally, the lack of
apparent DGC activity of CD0537’s might simply be due to a lack
of phosphorylation of its phosphoreceptor REC domain, a
modification that could be catalyzed by the putative kinase cheA
(CD0539) that was absent in our assay. Other DGCs have been
shown to be activated by phosporylation of their phosphoreceptor
REC domain [29,32,36]. As expected, CD1028 and CD2384,
which respectively possess the degenerated QKDMI and GGEEI
motifs, did not alter V. cholerae’s phenotypes. Consistent with our
observation, the substitution of the F residue of the A-site for an I
residue alone is known to eliminate the activity of WspR of P.
fluorescens [35].
Expression of several putative PDEAs (CD0757, CD1515,
CD1616, CD1840 and CD2663) significantly enhanced cell
motility on soft agar by 2 to 4 fold (Figure 3B and Table S1).
While five putative PDEAs exhibited significant activity (CD0204,
CD1421, CD1515, CD2134 and CD2663), in most cases, the
Figure 1. Domain composition and organization of the 37 putative c-di-GMP–signalling proteins encoded by C. difficile 630. Proteins
names are listed on the left and predicted sizes in amino acids are indicated on the right. GGDEF domains are shown in green and EAL domains are
shown in red. The DGC PleD from C. crescentus (YP_002517919) and the PDEA RocR from P. aeruginosa (NP_252636) are shown as references to
highlight amino acids important for enzymatic activity. The putative functions and positions of important amino acid residues [28,29] are listed above
each domain in black (conserved) or grey (non-conserved) and their position in PleD and RocR are indicated. Blue boxes are predicted signal peptide
regions. Black boxes represent predicted transmembrane regions. Grey boxes represent predicted coiled-coil motifs. Additional sensor domains
predicted by Pfam 24.0 are also shown in white. Proteins are not drawn to scale. Cache 1, Calcium channels and chemotaxis receptor family 1; PAS 3,
PAS fold family 3; PTS EIIC, Phosphotransferase system EIIC; REC, Response regulator receiver; SBP bac 3, Bacterial extracellular solute-binding
proteins, family 3; IP, primary inhibitory site; IS, secondary inhibitory site.
doi:10.1371/journal.pgen.1002039.g001
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was modest and not significant (Figure 3D). The weak response of
V. cholerae N16961 to PDEA activity could be due to its low basal
level of biofilm formation in our assays. However, we indirectly
confirmed that the V. cholerae motility response to overexpression of
these proteins was linked to PDEA activity by mutating the
glutamic acid residue of the EVLxR motif of CD0757, which is
critical for enzymatic activity. Indeed, unlike the wild-type protein,
overexpression of CD0757-E339A did not enhance the motility of
V. cholerae N16961 on soft agar (Figure 4A and 4C).
CD0522 has dual enzymatic activity
Since CD0522 has a particular combination of GGDEF and
EAL domains suggesting that it could have both DGC and PDEA
activities, it was analyzed apart from those in Figure 3. CD0522
contains two predicted N-terminal GGDEF domains and one
predicted C-terminal EAL domain (Figure 1 and Figure 4D). Our
analysis indicates that the first GGDEF domain and the EAL
domain should be catalytically active due to the conservation of
the A-sites. However, the second GGDEF domain contains the
strongly degenerated motif YADVF suggesting that it is catalyt-
ically inactive (Figure 1 and Figure 4D). CD0522 or its individual
domains were tested in our V. cholerae heterologous expression
model to verify these predictions (Figure 4C, 4E and 4F). Since the
variations of cell motility and biofilm formation we observed upon
ectopic expression of CD0522 were not statistically significant, we
could not clearly establish a DGC activity for the complete
CD0522. On the other hand, expression of the N-terminal
fragment N-448, which encompasses the first GGDEF domain,
reduced motility by more than half and increased biofilm by ,7
fold, suggesting that this fragment of CD0522 acts as a functional
DGC (Figure 4E and 4F). The observed phenotypes correlate with
a marked increase of intracellular c-di-GMP upon expression of N-
448 in V. cholerae N16961 compared to the same strain expressing
LacZ (Figure S2B and S2C, Text S1). DGC catalytic activity of
CD0522 was also indirectly confirmed by mutating the glutamic
acid residue of the EAL motif to abolish any possible PDEA
activity (Figure 4D). Expression of CD0522-E814A altered
phenotypes as expected for a DGC, as observed for N-448
(Figure 4C, 4E and 4F). Expression of the C-terminal fragment C-
307 led to a modest but significant increase of motility. As
expected, expression of the degenerated GGDEF-containing
central fragment M-305 did not lead to any significant change
of phenotype compared to the control. The degenerated GGDEF
domain of M-305 could be involved in the regulation of the PDEA
activity of the EAL domain of CD0522. We observed that motility
of cells expressing MC-591, which contains the central and C-
terminal fragments, increased by ,50% (Figure 4E), which is
consistent with a diminution of intracellular c-di-GMP. Increased
motility was also observed when we overexpressed CD0522-
G366E, a protein containing a substitution of the second glycine
Figure 2. Conservation of c-di-GMP–signalling components of
C. difficile 630 in other strains of C. difficile. (A) Protein orthologs
exhibiting $90% identity are indicated by dark grey boxes. More
divergent proteins sharing between 85 and 89% identity or containing
major gaps are indicated by light grey boxes. Proteins that are absent
are indicated by empty boxes. The c-di-GMP-sensing riboswitch Cd1
((RS) Cd1) and 84Cd aptamer from the tandem riboswitch-ribozyme
((RZ) 84Cd) are indicated by a dark gray box when they shared $90%
and were in the same genetic context as in strain 630. CdifQ2682,
CdifA2673, and CdifA6827 were used to refer to proteins CdifQCD-
2_020200002682 (ZP_05400016) from C. difficile QCD-23m63,
CdifA_020200002673 (ZP_05349638) and CdifA_020200006827
(ZP_05350459) from C. difficile ATCC 43255, respectively. (B) Phyloge-
netic tree of C. difficile isolates based on rpoB nucleotide sequences.
Bootstrap values are indicated at branch point in percent. Only values
$70% are shown.
doi:10.1371/journal.pgen.1002039.g002
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and 4E). Complex proteins such as CD0522 that are composed of
several GGDEF and EAL domains suggest a possible two-way c-
di-GMP control and must be studied in detail to reveal what
stimuli switches their enzymatic activity between the DGC or
PDEA state.
In vitro enzymatic assays
CD1420 and CD0757 enzymatic activities were further assessed
in vitro to corroborate the results obtained in the V. cholerae
expression model and confirm that the C. difficile proteins are
genuine DGC and PDEA, respectively. These proteins were
chosen for their strong activity in V. cholerae and the simplicity of
the structure of the N-terminal sensor domain that suggested little
requirements for in vitro assays (Figure 1). Purified CD1420 in its
native form was able to produce c-di-GMP from GTP as substrate
and the accumulation of the product increased with time
(Figure 5A). Conversely, purified CD0757 did not produce c-di-
GMP from GTP even after 1 h incubation. Therefore, we
confirmed that CD1420 is a functional DGC. The absence of
DGC activity of CD0757 suggests that it contains an inactive
GGDEF domain and acts as a PDEA only.
CD0757 was then assessed for PDEA activity on c-di-GMP. c-
di-GMP hydrolysis by PDEAs is known to yield the linear
diguanylate pGpG [37]. We incubated purified CD0757 with
radiolabeled c-di-GMP, yielding small amounts of pGpG. This
characteristic PDEA activity was abolished by denaturing the
protein prior to the assay (Figure 5B). Inactive GGDEF domains
have been shown to enhance PDEA activity of an adjacent EAL
domain by binding GTP [26]. Addition of GTP to the enzymatic
reaction increased noticeably the PDEA activity of CD0757
presumably through binding to the GGDEF domain like for PdeA
(CC3396) from C. crescentus. After a 30-min incubation period,
virtually all the c-di-GMP was converted to pGpG. Marginal
degradation of c-di-GMP to GMP by CD0757 was detected as
previously shown to occur with another PDEA [37].
Discussion
Studies on c-di-GMP have addressed with some depth many
aspects regarding the proteins involved in its synthesis (DGCs and
PDEAs) and the molecular targets of c-di-GMP such as proteins
and riboswitches in several bacteria. While c-di-GMP signalling
has been extensively studied in many Gram-negative bacteria like
Figure 3. Phenotypic changes triggered by the expression of C. difficile 630 genes encoding predicted DGCs or PDEAs in V. cholerae
N16961. Relative motility of cells over-expressing (A) predicted DGCs or (B) predicted PDEAs. Relative biofilm formation of mutant cells over-
expressing (C) predicted DGCs or (D) predicted PDEAs. V. cholerae over-expressing lacZ was used as a reference control. The means and standard
deviations obtained from at least three independent assays are shown. One-way ANOVA with a Dunnett multiple comparison post-test was used to
compare the strains over-expressing putative c-di-GMP signalling proteins and the control strain (LacZ) (*, P,0.05; **, P,0.01; ***, P,0.001).
doi:10.1371/journal.pgen.1002039.g003
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studies have been carried out on Gram-positive bacteria. To the
best of our knowledge, the staphylococcal GGDEF domain protein
GdpS has been the only c-di-GMP regulatory protein studied to
date in low G+C Gram-positive bacteria. GdpS does not seem to
have any measurable DGC activity [16]. The recent discovery of a
functional c-di-GMP binding riboswitch in C. difficile and Bacillus
cereus, as well as the prediction of several other similar riboswitches
in other Gram-positive bacteria has revived the interest in studying
c-di-GMP metabolism in these microorganisms. The recent
characterization of a c-di-GMP-dependent self-splicing group I
ribozyme in C. difficile further reinforces the role of c-di-GMP in
Gram-positive bacteria.
In this work, we have shown that many of the genes encoding
putative DGCs and PDEAs of C. difficile behave like genuine
DGCs and PDEAs in heterologous expression experiments
(Figure 3 and Figure 4, Table S1). This number of c-di-GMP
regulatory proteins encoded by C. difficile is high compared to what
is found in its closest relatives (Table S3), and also among the
Firmicutes in general (median=1) [38]. Analysis of the genomes of
49 strains of Clostridiaceae representing 27 species revealed that
most contain less than 20 of such genes (Table S3). Only 2 species
of Clostridium were found to encode more putative DGCs/PDEAs
than C. difficile, Clostridium asparagiforme DSM15981 and Clostridium
bolteae ATCC BAA-613, two newly characterized yet barely
studied species isolated from human fecal samples [39,40]. The
disparity in the occurrence of c-di-GMP signalling proteins is
remarkable. The two species coding for the lowest number of c-di-
GMP regulatory proteins, Clostridium hiranonis and Clostridium
bartlettii, are the closest phylogenetically related species to C.
difficile (Figure S3 and Table S3). On the opposite, the two species
coding for the highest number of GGDEF, EAL or HD-GYP
protein, C. asparagiforme and C. bolteae, are among the most distant
species from C. difficile. Additionally, C. difficile, which encodes with
one exception no HD-GYP domain proteins, seems to be an
exception among the Clostridiaceae and contrasts with Clostridium
beijerinckii which encodes 14 HD-GYP domain proteins (Table S3),
while retaining the same number of c-di-GMP regulatory proteins
as C. difficile. In addition, C. difficile does not seem to carry any gene
encoding c-di-GMP-signalling proteins that could have been
recently exchanged by horizontal transfer with the 3 other
Clostridium species containing the highest number of such proteins
(Table S3 and data not shown). The Clostridiaceae seem to have a
high number of c-di-GMP-signalling proteins among the Firmi-
cutes in general, but it remains similar to other Firmicutes of
comparable size (3000–4000 genes, median=10) [38].
The high number of c-di-GMP turn-over proteins in C. difficile is
likely indicative of the importance of this second messenger in the
bacterium’s lifecycle and suggests a major role in regulating
different phenotypes. The diversity of N-terminal structures
Figure 4. Alteration of V. cholerae N16961 motility and biofilm formation upon expression of wild-type or mutated putative DGCs
and PDEAs from C. difficile 630. (A) Relative motility upon expression of wild-type or mutated CD0757 or CD1420. (B) Relative biofilm expression
upon expression of wild-type or mutated CD0757 or CD1420. (C) Motility of the strain expressing the wild-type (WT) and mutated proteins on LB soft
agar plates at 30uC. The picture shown is representative of four independent experiments. (D) Schematic representation of CD0522 protein fragments
expressed. The amino acids in the signature motifs of the GGDEF or EAL domains are indicated above each domain. Positions of the mutations in the
GGDEF or EAL domains are indicated by asterisks. (E) Relative motility upon expression of full-length, mutated or truncated CD0522. (F) Relative
biofilm formation upon expression of full-length, mutated or truncated CD0522. The means and standard deviations obtained from four independent
assays are shown. One-way ANOVA with a Dunnett multiple comparison post-test was used to compare the cells over-expressing putative c-di-GMP
signalling proteins and the control strain (LacZ) (*, P,0.05; **, P,0.01; ***, P,0.001).
doi:10.1371/journal.pgen.1002039.g004
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proteins could individually act in a functionally or spatially
sequestered way, in addition to being temporally regulated
through differential expression. It has been shown that DGCs
usually are not interchangeable and can contribute to very specific
and distinct phenotypes for a unique microorganism. For example,
while the DGC YddV of E. coli impacts poly-N-acetylglucosamine
production, other DGCs like AdrA do not [41]. Instead AdrA
controls the production of cellulose, another exopolysaccharide, in
E. coli and Salmonella [42,43]. Furthermore, the prevalence of
DGCs and PDEAs in C. difficile could also indicate the importance
of these proteins in sensing and relaying a diversified array of
environmental conditions through their sensor domains or their
eventual differential expression. In V. cholerae, the PDEA CdpA is
not expressed in vivo until the late stage of infection in a mouse
colonization model [44]. C. difficile vegetative cells encounter
various environmental conditions during their journey through the
gastrointestinal tract, during which c-di-GMP signalling might
play a role in regulating diverse phenotypes.
Despite the current lack of experimental data, it is reasonable to
assume that c-di-GMP regulates at least two phenotypes in C.
difficile: flagella synthesis/motility and polysaccharide synthesis. A
putative c-di-GMP-binding PilZ domain is located in the putative
glycosyltransferase CD2545, which is predicted to be a cellulose
synthase. Interestingly, although motility is commonly controlled
by c-di-GMP in bacteria, the c-di-GMP-responsive effectors that
likely regulate this phenotype in C. difficile appear to differ from
those found in V. cholerae, E. coli and related bacteria. The c-di-
GMP-sensing riboswitch Cd1 appears to control the transcription
of the large operon of genes essential for assembling the flagellum
apparatus [22]. Bacterial flagella are obviously important for
motility but can also be involved in adhesion. Adhesion to mouse
cecal mucus of the flagellin FliC and of the flagellum cap protein
FliD of C. difficile has been demonstrated in vitro [45]. Moreover,
FliD has been shown to specifically adhere to cultured cells [45].
Therefore, c-di-GMP signalling might impact both cell motility
and adhesion of C. difficile to mucosal surface through the
regulation of flagellum assembly. Additionally, c-di-GMP signal-
ling may play a significant role in the excessive inflammation
caused by C. difficile infection since flagellin is a very potent
immunogenic protein recognized as a proinflammatory ligand by
toll-like receptor 5 (TLR-5) located at the baso-lateral surface of
intestinal cells (reviewed in [46]).
Except for one EAL protein (CD3650), all of C. difficile’s PDEAs
contain a GGDEF domain predicted to be non-catalytically active
as shown in vitro for CD0757 (Figure 1 and Figure 5). Composite
proteins containing both GGDEF and EAL domains are relatively
frequent, representing approximately one third of proteins with
such domains [47]. Some of these composite proteins act as
DGCs, PDEAs, or have both activities (reviewed in [47]). Inactive
GGDEF or EAL domains can act as sensor domains rather than
catalytic domains. GGDEF domain proteins with degenerated
active sites have been reported to bind c-di-GMP at their
conserved I-site, as for the C. crescentus protein PopA [48], or to
retain the ability to bind GTP at their degenerated active site, as
for the C. crescentus protein PdeA [26]. Christen and colleagues [26]
have demonstrated that binding of GTP to the inactive GGDEF
domain of PdeA of C. crescentus, strongly enhanced the PDEA
activity of the C-terminal EAL domain. The authors formulated
two hypotheses to explain why the PDEA activity is linked to GTP
intracellular concentrations: (i) to prevent GTP pools to drop by
the uncontrolled successive activities of DGCs and PDEAs and (ii)
to sense physiological changes. Intracellular GTP levels have been
shown to impact the activity of CodY, a major transcriptional
regulator in many low G+C Gram-positive bacteria such as C.
difficile, S. aureus, Streptococcus pneumoniae, Streptococcus pyogenes,
Streptococcus mutans, Listeria monocytogenes, B. cereus and Bacillus
anthracis in which it affects virulence gene expression ([49] and
references therein). CodY is known to have greater affinity to
target DNA promoter regions upon binding of two synergistic
Figure 5. TLC analysis of the enzymatic activities of CD1420 and CD0757. (A) DGC activity of purified CD1420. (B) PDEA activity of purified
CD0757. Snake venom phosphodiesterase (SVPD) was used as a positive control.
doi:10.1371/journal.pgen.1002039.g005
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CodY has been shown to repress the expression of the toxin A and
B genes (tcdA and tcdB), through binding to the promoter region of
the positive transcriptional regulator TcdR [52]. A recent study
aimed at identifying all DNA promoter regions targeted by C.
difficile CodY as well as genes differentially expressed in a codY null
mutant [49]. Interestingly, among the 165 genes identified with
altered expression, PDEA genes CD0757 and CD1476 were
highly derepressed. Additionally, DNA regions containing
CD1476, CD2385, CD2873, CD2965 and CD3650 were
identified as CodY binding-sites. These data suggest a probable
interplay between the c-di-GMP and CodY signalling pathways,
known to be important in the regulation of many metabolic genes
and of the major virulence factors, toxins A and B [49,52].
To the best of our knowledge, no model of Gram-positive
bacteria is currently available to efficiently and reliably evaluate
the enzymatic activity of proteins regulating the intracellular levels
of c-di-GMP. With the recent availability of molecular tools for C.
difficile genetic manipulation [53–55], it will finally be possible to
study in detail the many genes involved in c-di-GMP signalling
and turn-over in this bacterium and to identify the phenotypes
associated with the variation of intracellular c-di-GMP pools. The
need to decipher the regulatory mechanisms underlying C. difficile’s
behaviors is imperative to the development of new therapeutics
and treatment strategies. Particularly, the bacterial signalling
pathways and phenotypes involved at the colon mucosal interface
ought to be addressed.
Materials and Methods
Bioinformatics
Proteins containing the c-di-GMP-associated conserved domains
(GGDEF, EAL, HD for HD-GYP and PilZ) were searched for in
the Clostridiaceae proteomes on the Pfam 24.0 server [25]. HD
domains were further analyzed to identify HD-GYP domains by
looking for the HD-GYP amino acid motif by multiple alignment
with the HD-GYP domain of Rpfg from Xanthomonas campestris 8004
(Accession number AAY49388) using ClustalW version 2.0.12 [56].
Other conserved domains, signal peptides, transmembrane regions,
and coiled-coil motifs annotations are as determined on Pfam 24.0
[25]. Identification of proteins with c-di-GMP-associated conserved
domains in C. difficile strains other than 630 was achieved with the
hmmsearch program of the HMMER 3.0 software (http://hmmer.
org/). C. difficile annotated protein sequences were retrieved for the
13 other strains and 2 plasmids available in the NCBI Refseq
database (Table S2) [57]. Protein sequences from C. difficile
2007855, BI1, BI9, CF5, M120 and M68 genomes and extrachro-
mosomal sequences (Table S2) were predicted using Gene-
Mark.hmm for Prokaryotes version 2.4 [58]. Profile hidden Markov
models (profile-HMMs) of c-di-GMP-associated conserved domains
were downloaded from Pfam 24.0. The bit score threshold values
used in every search were the ‘‘trusted cutoff’’ values for the Pfam
profile-HMMs. Proteins containing the c-di-GMP-related con-
served domains identified using HMMER 3.0 software were further
analyzed to identify other conserved domains (Pfam 24.0), signal
peptides and transmembrane regions (Phobius [59]), and coiled-coil
motifs (ncoils [60]). Nucleotide and amino acid conservation of
selected C. difficile 630 genes and proteins were assessed with the
appropriate BLAST algorithms [61]. Since most of the genomes are
drafts, pseudogenes were ignored and assumed to be the results of
sequencing errors. As a matter of fact, pseudogenes are found in
manyofthesestrainsevenforimportant,uniqueandwell-conserved
genes such as the gene encoding DNA polymerase I (data not
shown).
Phylogenetic trees were generated using the neighbor-joining
method as implemented by ClustalX version 2.012 [56] from
gapless alignments of nucleotide sequences. Nucleotide sequences
were aligned using ClustalW version 2.0.12 [56] and gap columns
were removed using Jalview version 2.5 multiple alignment editor
[62]. The reliability of each tree was subjected to a bootstrap test
with 1000 replications. Trees were edited using FigTree version
1.3.1 (http://tree.bio.ed.ac.uk/software/figtree/).
Growth conditions
Bacterial strains were routinely grown in Luria–Bertani (LB)
broth at 37uC in an orbital shaker and maintained at 280uCi nL B
broth containing 15% (v/v) glycerol. Ampicillin (Ap) was used at
100 mgm l
21 when needed. For induction of gene expression in
the strains carrying arabinose-inducible vectors (pBAD series), L-
arabinose was added to the growth medium at a final
concentration of 0.02% (w/v).
Bacterial strains and plasmid construction
The bacterial strains and plasmids used in this study are
described in Table S4. The oligonucleotides used for plasmid
constructions are described in Table S5. For expression of putative
DGCs and PDEAs in V. cholerae, genes cloned in pBAD-TOPO
were amplified by PCR with their native Shine-Dalgarno sequence
using C. difficile 630 genomic DNA as a template. Truncated
versions of CD0522 were cloned to include the native Shine-
Dalgarno sequence of CD0522. DNA was amplified to express
CD0522 protein fragments N-448, M-305, C-307 and MC-591
respectively containing the N-terminal 448 amino acids (aa), 305
aa encompassing the middle domain, the 307 aa in C-terminal and
591 aa encompassing the middle and C-terminal domains
(Figure 4D).
Plasmids pCD0522-G366E, pCD0522-E814A, pCD0757-
E339A and pCD1420-G204E, which accordingly contain amino
acid substitutions in their respective conserved GG[D/E]EF or
EXL A-sites, were created by site-directed mutagenesis of
pCD0522, pCD0757 and pCD1420 using the QuickChange
Lightning Site-directed Mutagenesis Kit (Stratagene) using primer
pairs listed in Table S5. The mutations introduced were designed
to create new EarI or PvuII restriction sites for initial screening of
the mutated plasmids. Mutated genes were verified by sequencing.
For CD0757 and CD1420 proteins purification, the corre-
sponding genes were amplified by PCR from C. difficile 630
genomic DNA and cloned into BamHI/SalI-digested pGEX6P-1
in frame with the glutathione S-transferase (GST) coding
sequence.
Molecular biology methods
All the enzymes used in this study were obtained from New
England BioLabs and were used according to the manufacturer’s
instructions. Plasmid DNA was prepared with a Qiaprep Spin
miniprep kit (Qiagen). Genomic DNA of C. difficile 630 was
extracted using the illustra bacteria GenomicPrep mini spin kit
(GE Healthcare). PCR assays were performed with the primers
described in Table S4 in 50 ml of PCR mixtures with 1 U of Pfu
Ultra DNA polymerase (Agilent). PCR conditions were as follows:
(i) 3 min at 94uC, (ii) 30 cycles of 30 s at 94uC, 30 s at suitable
annealing temperature, and 30–300 s at 72uC, and (iii) 5 min at
72uC. When needed PCR products were purified using a
QIAquick PCR Purification Kit (Qiagen) according to the
manufacturer’s instructions. E. coli was transformed by electropo-
ration according to Dower and colleagues [63]. V. cholerae was
transformed by electroporation according to Occhino and
colleagues [64]. In both cases, transformation was carried out in
c-di-GMP Turn-Over in Clostridium difficile
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apparatus set at 25 mF, 200 V and 1.8 kV.
Motility and biofilm formation assays
Motility and biofilm assays were performed as described before
[32]. Briefly, a semi-solid medium composed of 1% tryptone, 0.5%
NaCl, 0.3% agar supplemented with ampicillin and L-arabinose
was used to evaluate motility of V. cholerae mutant strains during
over-expression assays at 30uC. Motility was assessed from the
comparison of the surface area (mm
2) of the colonies from plate
images captured and analyzed using a Gel Doc XR system and
Quantity One software (Bio-Rad).The capacity of V. cholerae mutant
strains to form biofilm was determined after 6 h static growth in LB
broth containing ampicillin and L-arabinose at 30uC. Bound crystal
violet was solubilized with 200 ml of 95% ethanol and quantified by
absorbance at 595 nm in a Model 680 microplate reader (Bio-Rad).
Motility and biofilm formation assays were carried in triplicate and
data were normalized as fold expression compared with the control
LacZ over-expressing bacteria. Data from at least three indepen-
dent experiments were combined.
Production of recombinant proteins
Overnight-grown cultures of E. coli BL21 bearing pGCD0757
or pGCD1420 were diluted 1:100 in fresh 26 YTA broth and
incubated at 37uC with agitation. Protein expression was induced
with 0.1 mM IPTG (isopropyl 1-thio-b-D-galactopyranoside) at
mid-exponential phase (OD600 of 0.6) for CD0757 or at late-
exponential phase (OD600 of 1.2) for CD1420. The cultures were
grown for an additional 4 h at 37uC for CD0757 or 2 h at 25uC
for CD0757. Cells were collected by centrifugation, re-suspended
in PBS containing 1% Triton X-100 and protease inhibitors
(Protease Inhibitor Cocktail, Sigma), and lysed by sonication.
CD0757 and CD1420 were recovered by affinity chromatography
using the GST purification module (GE Healthcare) with the
PreScission protease (GE Healthcare) according to the manufac-
turer’s instructions. After elution, proteins samples were dialyzed
against the conservation buffer (50 mM Tris-HCl pH 7.8,
250 mM NaCl, 25 mM KCl, 10 mM MgCl2, 30% glycerol) for
18 h in D-Tube Dialyzer Maxi (MWCO 12–14, Novagen),
concentrated by centrifugation on Amicon Ultra-15 columns
(MWCO 10, Millipore), and stored at 220uC. Protein concen-
tration was estimated using a BCA Protein Assay Kit (Thermo-
Scientific) and purity was determined by SDS-PAGE analysis.
Assays for enzymatic activity and TLC analysis
Diguanylate cyclase and phosphodiesterase activities were
measured according to previously described procedures [32,37]
with the following modifications. Diguanylate cyclase assays were
performed with approximately 1–2 mg of purified proteins in a
final volume of 50 ml. Reaction mixtures were pre-incubated for
5 min at 30uC in the reaction buffer (50 mM Tris-HCl pH 7.8,
250 mM NaCl, 25 mM KCl, 10 mM MgCl2). DGC reactions
were initiated by adding 33.3 nM [a-
33P]-GTP (0.1 mCi ml
21) and
incubated at 30uC. Samples were taken at various times, and the
reactions were stopped by addition of one volume 0.5 M EDTA.
Radiolabeled c-di-GMP for phosphodiesterase activity assays was
synthesized using purified DgcK [32]. Purified DgcK (30 mg) was
incubated 8 h at 30uC in the reaction buffer to completely convert
[a-
33P]-GTP into c-di-GMP. Reactions were stopped by denatur-
ing at 99uC for 15 min, centrifuged for 2 min at 16,000 g to
elimate DgcK and recover the supernatant containing the
radiolabeled c-di-GMP. Phosphodiesterase assays were performed
with approximately 1–2 mg of purified proteins in a final volume of
50 ml of reaction buffer containing 20 nM prepared radiolabeled
c-di-GMP (0.1 mCi ml
21) with or without 100 mM GTP. One unit
of snake venom phosphodiesterase (Phosphodiesterase I,
Worthington) suspended in SVPD conservation buffer (100 mM
Tris-HCl pH 8.0, 100 mM NaCl, 14 mM MgCl2, 50% glycerol)
was used as a positive control in PDEA assays. Proteins denatured
at 99uC for 15 min were used as negative controls in both DGC
and PDEA assays. Reaction products were analyzed by TLC as
described before [32]. Briefly aliquots (2–4 ml) were spotted on
polyethyleneimine-cellulose TLC plates (Sigma) previously washed
in 0.5 M LiCl and air dried. Plates were then soaked for 5 min in
methanol, dried, and developed in 2:3 (v/v) saturated (NH4)2SO4/
1.5 M KH2PO4 (pH 3.5). Plates were allowed to dry prior to
exposition to a phosphor imaging screen (Molecular Dynamics).
Data were collected and analyzed using a FX molecular imager
and the Quantity One software (Bio-Rad).
Supporting Information
Figure S1 Domain composition and organization of the 3
putative c-di-GMP-signalling proteins encoded by C. difficile strains
other than strain 630. Domain composition and organization of
the proteins are depicted essentially as in Figure 1. The HD-GYP
domain is colored in orange.
(TIF)
Figure S2 Analysis of intracellular c-di-GMP by HPLC. 10 mM
synthetic c-di-GMP (A), nucleotide extracts from V. cholerae
N16961 expressing lacZ from pBAD-TOPO/lacZ/V5-His (nega-
tive control) (B), the DGC N-448 from pCD0522-(N-448) (C), or
the DGC CD1420 from pCD1420 (D). Spectra of synthetic c-di-
GMP (E), and of peaks with corresponding retention times in the
nucleotide extracts from V. cholerae N16961 expressing the DGC
N-448 (F) or the DGC CD1420 (G). 100 mg of cells were used for
all nucleotide extractions.
(TIF)
Figure S3 Phylogenetic tree of selected Clostridiaceae species.
The tree was generated by alignment of the rpoB sequences using
the neighbor-joining method. The support for each branch is
indicated by the value at each node (in percent) as determined by
1,000 bootstrap samples. Only values $70% are shown.
Staphylococcus aureus COL and Bacillus subtilis 168 were taken as
outgroup strains. Colored boxes highlight the Clostridium difficile
strains (cyan), the two Clostridiaceae strains with the most c-di-
GMP regulatory proteins (yellow) and the two Clostridiaceae
strains with the least c-di-GMP regulatory proteins (magenta).
Total c-di-GMP regulatory proteins per species are shown in
parenthesis next to colored boxes.
(TIF)
Table S1 Predicted and observed activities of the 31 most
conserved putative c-di-GMP turn-over proteins.
(DOC)
Table S2 Accession numbers of genomes of C. difficile strains
used in this study.
(DOC)
Table S3 Clostridiaceae-encoded proteins containing GGDEF,
EAL, or HD-GYP domains.
(DOC)
Table S4 Bacterial strains and plasmids used in this study.
(DOC)
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